Acesso livre
Acesso livre

Arquivos do dia: Outubro 19, 2021

Estudo RECOVERY | Em pacientes internados com COVID-19, colchicina não reduziu a mortalidade em 28 dias, a permanência no hospital ou o risco de progressão para ventilação mecânica invasiva.

19 Out, 2021 | 12:55h

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Respiratory Medicine

Conteúdos relacionados:

Revisão sistemática | Colchicina para tratamento de COVID-19 – Não há benefício para pacientes hospitalizados; evidências inconclusivas para o tratamento de pacientes não internados mostram que “é provável que reduza levemente a necessidade de hospitalização ou morte em 28 dias, em comparação ao placebo.”

19 Out, 2021 | 12:54h

Colchicine for the treatment of COVID‐19 – Cochrane Library

Conteúdos relacionados:

 

Comentário no Twitter

 

Consequências de longo prazo do mau uso de dados sobre ivermectina.

19 Out, 2021 | 12:52h

Long-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases

Conteúdos relacionados:

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 

Comentário no Twitter

 

Editorial | Preparação para a “doença X”.

19 Out, 2021 | 12:50h

Preparing for “Disease X” – Science

Vacinas da China contra a COVID foram cruciais – agora, a imunidade está diminuindo.

19 Out, 2021 | 12:49h

China’s COVID vaccines have been crucial — now immunity is waning – Nature

Conteúdos relacionados:

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Comissão BJS sobre cirurgia e cuidado perioperatório pós-COVID-19.

19 Out, 2021 | 12:47h

BJS commission on surgery and perioperative care post-COVID-19 – British Journal of Surgery

Conteúdo relacionado: Cohort Study: Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries.

 

Comentário no Twitter

 

Diretriz | Manejo de agentes anticoagulantes e antiplaquetários na cirurgia cutânea.

19 Out, 2021 | 12:46h

S3 guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery – Journal of the German Society of Dermatology

Mais um estudo observacional sugere que rivaroxabam está associado com taxas mais altas de sangramento gastrintestinal do que outros anticoagulantes orais diretos (DOACs).

19 Out, 2021 | 12:44h

Rivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

Comentário: Rivaroxaban Again Linked to More Bleeding vs Other DOACs – TCTMD

Conteúdo relacionado: Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study – Gastroenterology

 

Comentário no Twitter

 

Estudo randomizado por cluster | Uma intervenção de exercícios pode melhorar o sucesso acadêmico entre crianças.

19 Out, 2021 | 12:42h

Exercise Intervention for Academic Achievement Among Children: A Randomized Controlled Trial – Pediatrics

 

Comentário no Twitter

 

Revisão sistemática | Bloqueadores dos canais de cálcio (BCC) vs. outras classes de medicamentos para hipertensão – “Há evidências de certeza moderada de que diuréticos reduzem eventos cardiovasculares maiores e insuficiência cardíaca congestiva mais do que os BCC.”

19 Out, 2021 | 12:41h

Resumo: Calcium channel blockers versus other classes of drugs for hypertension – Cochrane Library

Estudo original: Calcium channel blockers versus other classes of drugs for hypertension – Cochrane Library

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.